I believe the information regarding sorafenib is contradictory. There have been releases this year regarding the improvements in expectancy when using sorafenib to treat liver cancer. Worth noting, the results presented at the ASCO conference in June indicated approximately a 3-month overall improvement in survival. (from 7.9 months on "standard" treatments to 10.7 months on the sorafenib protocol)
That being said, similar improvements have not been seen in cholangiocarcinoma when treated with sorafenib alone. I think you will see this reflected by some of the patients on this site that participated in the sorafenib study that was recruiting people in late 2005/early 2006. Of course, no two patients on this site seem to respond similarly, so what is good/bad for one does not necessarily translate for the rest of the community.
There is a paper coming out of Germany that indicates MS-275 used alone, or in conjunction with anticancer agents (such as sorafenib) inhibits the growth of human cholangiocarcinoma cells. This study is coming from the bench, and I am unaware of any clinical trials emerging from this early study. But I'm including the text of the abstract in the research section in the event that anyone is interested in reading.